

Via Telefacsimile: 571-273-0140

RECORDATION FORM COVER SHEET
PATENTS ONLY

Attorney Docket Number
10589-043-999
(CAM No. 109843-999042)

Mail Stop Assignment Recordation Services
Director of the United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Please record the attached original documents or copy thereof.

| | | | | | | | | | | | | | |
|--|--|---|--------|---|--|--|--------|---|--|------------------------|----------|-----------|------|
| <p>1. Name of conveying party(ies): PTC Therapeutics, Inc.</p> <p>Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p> | <p>2. Name and address of receiving party(ies):</p> <p>Name: <u>Amgen Inc.</u></p> <p>Address: <u>One Amgen Drive</u> <u>Thousand Oaks, California</u></p> <p>Country (if other than USA): Zip Code: <u>91320</u></p> <p>Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p> | | | | | | | | | | | | |
| <p>3. Nature of conveyance:</p> <p><input checked="" type="checkbox"/> Assignment Merger</p> <p>Security Agreement Change of Name</p> <p>Other</p> <p>Execution Date: <u>May 24, 2006.</u></p> | | | | | | | | | | | | | |
| <p>4. Application number(s) or patent number(s):</p> <p>If this document is being filed together with a new application, the execution date of the application is:</p> <p>A. Patent Application No.(s) <u>11/048,659</u> B. Patent No.(s)</p> <p align="center">Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p> | | | | | | | | | | | | | |
| <p>5. Name and address of party to whom correspondence concerning document should be mailed:</p> <p>JONES DAY 222 East 41st Street New York, New York 10017</p> | <table border="1" style="width:100%; border-collapse: collapse;"> <tr> <td style="width:70%;">6. Number of applications and patents involved:</td> <td style="width:30%;">One</td> </tr> <tr> <td colspan="2">7. Total fee (37 CFR 3.41):.....\$ 40.00 Please charge to the deposit account listed in Section 8.</td> </tr> <tr> <td colspan="2">8. Deposit account number: <u>50-3013</u></td> </tr> </table> | 6. Number of applications and patents involved: | One | 7. Total fee (37 CFR 3.41):.....\$ 40.00 Please charge to the deposit account listed in Section 8. | | 8. Deposit account number: <u>50-3013</u> | | | | | | | |
| 6. Number of applications and patents involved: | One | | | | | | | | | | | | |
| 7. Total fee (37 CFR 3.41):.....\$ 40.00 Please charge to the deposit account listed in Section 8. | | | | | | | | | | | | | |
| 8. Deposit account number: <u>50-3013</u> | | | | | | | | | | | | | |
| DO NOT USE THIS SPACE | | | | | | | | | | | | | |
| <p>9. Statement and signature.</p> <p><i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i></p> <table style="width:100%;"> <tr> <td style="width:25%;">Anthony M. Insogna</td> <td style="width:10%;">35.203</td> <td style="width:40%;"><u>Anthony M. Insogna, Reg. No. 35,203</u></td> <td style="width:25%;"></td> </tr> <tr> <td>Michael J. Bruner</td> <td>47,458</td> <td><u>By: Michael J. Bruner, Reg. No. 47,458</u></td> <td></td> </tr> <tr> <td>Name of Person Signing</td> <td>Reg. No.</td> <td>Signature</td> <td>Date</td> </tr> </table> <p align="right">May 30, 2006</p> | | Anthony M. Insogna | 35.203 | <u>Anthony M. Insogna, Reg. No. 35,203</u> | | Michael J. Bruner | 47,458 | <u>By: Michael J. Bruner, Reg. No. 47,458</u> | | Name of Person Signing | Reg. No. | Signature | Date |
| Anthony M. Insogna | 35.203 | <u>Anthony M. Insogna, Reg. No. 35,203</u> | | | | | | | | | | | |
| Michael J. Bruner | 47,458 | <u>By: Michael J. Bruner, Reg. No. 47,458</u> | | | | | | | | | | | |
| Name of Person Signing | Reg. No. | Signature | Date | | | | | | | | | | |
| Total number of pages including cover sheet: two | | | | | | | | | | | | | |

Mail documents to be recorded with required cover sheet information to:
Mail Stop Assignment Recordation Services
Director of the United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
Or fax documents to Fax No.: 571-273-0140

CH \$40.00 503013 11048659

700267341

PATENT
REEL: 017710 FRAME: 0614

SOLE

ASSIGNMENT

WHEREAS, the inventors, RICHARD G. WILDE, NEIL G. ALMSTEAD, ELLEN M. WELCH, and HOLGER BECKMANN, by an Assignment executed June 20, 2005; June 20, 2005; June 20, 2005; and June 9, 2005, respectively, which was recorded in the United States Patent and Trademark Office on August 1, 2005, at Reel 016831/Frame 0494, have assigned their full right, title and interest in and to the invention set forth in U.S. application Serial No. 11/048,659, filed January 21, 2005, entitled USE OF NUCLEOTIDE COMPOUNDS FOR NONSENSE SUPPRESSION AND THE TREATMENT OF GENETIC DISEASE to PTC Therapeutics, Inc., a Delaware corporation having a place of business at 100 Corporate Court, Middlesex Business Center, South Plainfield, New Jersey 07080 ("Assignor"); and

WHEREAS, Assignor has taken the entire right, title and interest in the above-mentioned patent application; and

WHEREAS, Amgen Inc., a Delaware corporation having a place of business at One Amgen Drive, Thousand Oaks, California 91320 ("Assignee"), successor in interest to Tularik Inc., is entitled to acquire an undivided one-half (1/2) interest in said invention and patent application pursuant to an exclusive license agreement between the Assignor and the Assignee as set forth in the Termination and License Agreement dated December 6, 2002 between PTC Therapeutics, Inc. and Tularik Inc.; and WHEREAS, Assignor is willing to assign such an interest therein to Assignee while Assignor retains an undivided one-half (1/2) interest.

NOW, THEREFORE, in consideration good and valuable consideration, including that which is set forth in the Termination and License Agreement dated December 6, 2002 between PTC Therapeutics, Inc. and Tularik Inc., the receipt of which is hereby acknowledged, Assignor, through its legal representative, does hereby assign, sell, and transfer to Assignee, its successors, assigns and legal representatives, an undivided one-half (1/2) interest in the invention set forth above for the United States, and all divisions, renewals and continuations thereof, and all Patents of the United States which may be granted thereon and all reissues and extensions thereof; and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may hereafter be filed for said invention in any country or countries foreign to the United States, together with the right to file such applications and the right to claim for the same the priority rights derived from said United States application under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable; and all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and designs which may be granted for said invention in any country or countries foreign to the United States and all extensions, renewals and reissues thereof;

AND Assignor, through its legal representative, authorizes and requests the Commissioner for Patents and any Official of any country or countries foreign to the United States, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to the said Assignee, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND Assignor, through its legal representative, covenants and agrees that it has full right to convey the undivided one-half (1/2) interest herein assigned, and that it has not executed, and will not execute, any agreement in conflict herewith.

IN TESTIMONY WHEREOF, Mark Boulding, Esq. as legal representative of PTC Therapeutics, Inc. has hereunto set his signature this 24 day of May, 2006.


PTC Therapeutics, Inc.
100 Corporate Court, Middlesex Business Center
South Plainfield, New Jersey 07080

By: 
Mark Boulding, Esq.
Senior Vice President, Business Development & Legal

State of New Jersey)
) SS.:
County of Middlesex)

On May 24, 2006, before me, Sonja Benson, Notary Public, personally appeared Mark Boulding, personally known to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal



SONJA K. BENSON
NOTARY PUBLIC OF NEW JERSEY
Commission Expires 12/17/2007

PATENT

RECORDED: 05/30/2006

REEL: 017710 FRAME: 0615